The remodelling of actin composition as a hallmark of cancer✩

Rahul Suresh a, Roberto J. Diaz b,∗

a Montreal Neurological Institute, Integrated Program in Neuroscience, McGill University, Montreal, Canada
b Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Faculty of Medicine, McGill University, Montreal, Canada

A R T I C L E   I N F O

Keywords:
Actin
Cancer
Neoplasia
Transformation
Migration
Cytoskeleton

A B S T R A C T

Actin is a key structural protein that makes up the cytoskeleton of cells, and plays a role in functions such as division, migration, and vesicle trafficking. It comprises six different cell-type specific isoforms: ACTA1, ACTA2, ACTB, ACTC1, ACTG1, and ACTG2. Abnormal actin isoform expression has been reported in many cancers, which led us to hypothesize that it may serve as an early biomarker of cancer. We show an overview of the different actin isoforms and highlight mechanisms by which they may contribute to tumorigenicity. Furthermore, we suggest how the aberrant expression of actin subunits can confer cells with greater proliferation ability, increased migratory capability, and chemoresistance through incorporation into the normal cellular F-actin network and altered actin binding protein interaction. Studying this fundamental change that takes place within cancer cells can further our understanding of neoplastic transformation in multiple tissue types, which can ultimately aid in the early-detection, diagnosis and treatment of cancer.

Introduction

Actin is an important and prominent structural protein that is found in all cells of the body and has a role in multiple cellular functions such as division, migration, chromat in remodelling, and vesicle trafficking. This cytoskeletal protein is composed of several isoforms, all which contribute to its diverse range of functions. Notably, these isoforms mainly differ from one another at their N-terminal amino acid sequence, but it is currently unclear whether these regions are responsible for the unique function of each isoform (Fig. 1) [1,2]. In birds and mammals, four of these isoforms are primarily expressed in skeletal, smooth, and cardiac muscle: a smooth-actin 1 (ACTA1), a smooth-actin 2 (ACTA2), α cardiac-actin 1 (ACTC1), and γ smooth-actin 2 (ACTG2). The other two isoforms, which are ubiquitously expressed, are β cytos-actin (ACTB) and γ cytos-actin 1 (ACTG1) [2]. The varying α, β, and γ subunits play important roles in cell motility, structure, integrity, and intracellular signalling [1,2]. Interestingly, dysregulation of their functions is often found during malignant transformation of normal cells [3]. This led us to hypothesize that altered actin subunit expression is a hallmark of neoplasia with implications in migration and cell survival. In this review, we look at how an abnormal actin cytoskeleton interacts with tropomyosin, tropomodulin and actin binding proteins (ABPs) to confer neoplastic properties to normal cells [4,5]. Additionally, we elucidate how early changes to the actin cytoskeleton composition alters rates of actin turnover, F-actin stability, and interactions with actin binding proteins. Lastly, we suggest how this enables oncogenic processes such as increased migration, cell proliferation, and survival in multiple tissue types.

Basic overview of actin dynamics

The inherent ability of actin to exert the aforementioned functions within cells depends on the polymerization and depolymerization capabilities of actin fibers. Briefly, the genes encoding actin are first transcribed and translated into globular monomers (G-actin). These actin monomers join the rapidly growing barbed (+)-end of the filament in the more stable ATP-state to form fibrous strands (F-actin) which function to maintain structural integrity, support migration, and accomplish cell division [1,2]. Then, ATP-hydrolysis takes place within the F-actin, and this causes the ADP-monomers to begin to dissociate from the pointed (-) end faster than the ATP-bound ones [1]. This process of steady-state polymerization and depolymerization is known as treadmillng (Fig. 2) [1].

However, the actual rates of filament assembly and disassembly are modulated by actin binding proteins (ABPs). One of these ABPs is Arp2/3 whose main function is to create branch points by nucleating the assembly of filaments and also acts to form cross-links [6]. Another well-known actin nucleator is a class of proteins known as formins which have an instrumental role in enhancing the nucleation of actin filament assembly, the bundling of filaments, and binding to the barbed ends to influence the rate of elongation of actin fibers [7]. The actin depolymerizing factor (ADF)/cofilin family of proteins serve many functions

✩ Conflict of Interest: On behalf of all authors, the corresponding author states that there is no conflict of interest

∗ Corresponding author.
E-mail address: roberto.diaz@mcgill.ca (R.J. Diaz).

https://doi.org/10.1016/j.tranon.2021.101051
Received 28 December 2020; Received in revised form 1 February 2021; Accepted 17 February 2021
1936-5233/© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
Fig. 1. A schematic representation of the different actin isoforms. Top panel - karyotype marking of the particular chromosome with the locus of each actin gene marked in red. Bottom panel – actin fibre schematic with regions of variability at the N-terminus of each actin isoform. Regions of the same colour represent an identical amino acid sequence.

within the cell. It is responsible for producing the high rate of turnover which actin monomers are known to experience. Additionally, it functions to depolymerize, nucleate, promote the disassembly of ADP-actin monomers, and also sever actin filaments [6]. While ADF/cofilin dissociates ADP-actin from the pointed end, an ABP called profilin adds ATP-actin to the barbed end, thereby growing the actin filament [6]. Conversely, Gelsolin is an ABP that functions to sever the actin filament as well as to cap the severed ends, thereby preventing re-annealing of the monomers [6]. As the monomers within the polymerized filament “age”, their ATP becomes hydrolysed to ADP, thereby causing them to dissociate [6]. Thus, capping proteins such as profilin, gelsolin and CapZ bind to the barbed-end of the actin filament to regulate actin dynamics by blocking the addition and loss of actin subunits [8]. On the other hand, tropomodulin (Tmod) is a capping protein that binds to the pointed-
end of the actin filament (strongly in the presence of tropomyosin) to regulate filament length and assembly [6].

The last actin binding protein that this review will highlight is tropomyosin, because its altered expression levels are closely associated with the rearrangement of microfilament bundles, altered cell morphology, as well as increased cell motility [9]. Its primary role is to stabilize actin filaments to promote filament elongation by reducing the probability of filament severing [10]. It also plays a very important role in determining the steady-state polymerized actin levels within the cell [10]. Notably, the location of tropomyosin on the actin fibers suggests the possibility of competitive binding between tropomyosin and other actin binding proteins [11]. Overall, there are many ABPs present within the cell and they all have an important role in modulating actin dynamics under normal physiological conditions.

**Non-redundant roles of the different actin isofoms**

Several knockout experiments have been performed in order to elucidate the role of each actin isoform. ACTA1, ACTB and ACTC1 knockouts were embryonic, perinatal or postnatal lethal, whereas knocking out ACTG1, ACTG2, and ACTA2 led to a viable organism with many cardiac, muscular, and vascular developmental defects [12–18]. In ACTC1 knockout mice, a partial rescue was possible by heart-specific ACTG2 expression, but the hearts were hypodynamic, considerably enlarged, and had lower contractility [16,19]. Similarly, ACTG1 can be expressed in ACTA1-knockout mice for a partial rescue that yields some developmental defects, still without completely restoring ACTA1 function [15,19]. Knockout phenotypes of ACTB and ACTG1 are vastly different despite these non-muscle actins showing similar sequence homology, biochemical properties, and coexisting within the same cells [12–14,18,19]. Interestingly, exogenously expressed smooth muscle actin incorporates into stress fibers in smooth muscle cells, but not in endothelial cells [20]. Furthermore, non-muscle actin subunit expression in both muscle and non-muscle cell types results in altered cell shape and poorly formed stress fiber network [20]. These experiments support the hypothesis that actin isoforms have distinct functions depending on subunit type and the cell type in which they are expressed.

Notably, the directions for the functional complexity of each isoform may lie in their mRNA sequence. Work by Vedula et al. showed that although the amino acid sequence at the N-termini of both ACTB and ACTG1 are very similar, editing the nucleotide sequence of ACTG1 to encode an ACTB-like protein can compensate for the loss of ACTB [21]. This suggests that although the major differences between the isoforms are found at the level of their amino acids, the mRNA sequence may be more important in determining the ultimate protein function since it directs the rate of synthesis and type of secondary protein modifications [21,22]. Ultimately, as this review further elaborates, the differences present within the genes encoding each isoform are associated with a particular set of neoplastic functions.

**ACTA1**

ACTA1 is a gene that encodes the skeletal muscle α-actin which is the main isoform found in skeletal muscle, and is essential for muscle contraction [23]. Bioinformatics analyses have revealed that ACTA1 gene expression is altered in many cancers. For example, it is downregulated in head and neck squamous cell carcinomas and this is associated with tumorigenesis [24,25]. This decrease in ACTA1 expression can serve as a prognostic marker for the poor clinical outcome of head and neck squamous cell carcinoma patients (Table 1) [24,25]. Similarly, it is downregulated in colorectal cancer, prostate cancer, and pancreatic adenocarcinoma through DNA hypermethylation and this is associated with aggressive carcinogenesis (Table 1) [26–29]. In prostate cancers with the PTEN mutation, ACTA1 expression is significantly correlated with shorter patient survival [30,31]. Interestingly, stromal fibroblasts in prostate cancer tissue samples show increased expression of the cancer-associated fibroblast marker ACTA1 (Table 1) [31]. The presence of ACTA1 expressing fibroblasts in the prostate cancer stroma is associated with increased tumour metastatic potential [31]. In the case of oral squamous cell carcinoma, high expression of ACTA1 is associated with shorter survival (Table 1) [32]. Additionally, in basal-like breast cancer, ACTA1 is a biomarker that is associated with chemoresistance (Table 1) [33].

There are many possible mechanisms by which the ACTC1 protein promotes oncogenesis. One possibility could be through annexins which are Ca²⁺-dependent, phospholipid-binding proteins that function in vesicle trafficking, cell proliferation and apoptosis. Annexin expression is correlated with shorter survival, tumorigenesis, and the progression of malignant ovarian cancer. Notably, annexins have extensive physical interactions with ACTA1 [34]. ACTA1 could also regulate cell migration through its involvement in the integrin-signalling pathway (Fig. 2) [35]. More specifically, during conditions of mechanical strain on normal skeletal muscle, integrin β1-mediated signalling results in the activation of RhoA which induces the activity of several promoters, one being that of ACTA1, thereby increasing the cytoplasmic levels of the ACTA1 subunit [36]. Another downstream protein that is activated by RhoA is RhoA kinase (ROCK), which will result in the inhibition of the F-actin-severing ability of the protein coflin [37]. This in turn will promote stress fiber formation [37]. When ACTA1 subunits are aberrantly expressed in the cytoplasm, more of them are readily available to form F-actin and stress fibers, which are implicated in cytoskeletal stabilization, cell survival, migration and proliferation, all of which are downstream of the integrin-signalling pathway [37].

In the case of pancreatic ductal adenocarcinoma, expression of ACTA1 is a characteristic feature of cancer-associated fibroblasts (Fig. 2) [38]. Stromal progenitor cells and fibroblast-like cells show increased ACTA1 expression when undergoing a morphological change from a spherical to flattened phenotype (Fig. 2) [39]. Coincidentally, this change in cell shape also occurs during the epithelial-mesenchymal transition of cells undergoing malignant transformation, and confers a more migratory phenotype to cells [40].

**ACTA2**

ACTA2 is a gene that encodes for smooth-muscle actin found in the vasculature. It is primarily located in the microfilaments bundles of smooth muscle cells and functions in its contractility (i.e. during body temperature homoeostasis) [41]. Interestingly, increased ACTA2 expression is also associated with more distant metastasis and unfavourable prognosis of lung adenocarcinoma, HER2+ breast cancer, early-onset colorectal cancer, bladder cancer, and non-small cell lung cancer (Table 1) [42–46]. Furthermore, the acquisition of ACTA2 is found in “activated” myofibroblastic cancer-associated fibroblasts of head and neck cancers, colorectal cancer, and pancreatic cancer (Table 1) [47–49].

Mechanistically, ACTA2 plays an important role in the contractility of myofibroblasts, and its elevated levels serve as a marker for oncogenic transformation of these cancer-associated fibroblasts (Fig. 2) [50]. Lee et al. [44], previously reported that ACTA2 regulates c-MET and FAK expression, as well as positively influences the metastatic potential of lung adenocarcinoma, and affects the prognosis (Fig. 2) [44,51]. Work by Milewicz et al. [52], showed that ACTA2 proliferative and secretory activities as well as transition from a contractile to a synthetic phenotype was the underlying mechanism of vasculogenesis [41,52]. Furthermore, explanted smooth muscle cells and myofibroblasts from patients with mutations in ACTA2 revealed that the increased proliferation of smooth muscle cells contributed to occlusive diseases. Mutations to the ACTA2 gene can also lead to smooth muscle cell proliferation and subsequent remodelling of the vascular wall [41]. Taken together, this suggests that deregulated α-subunit expression can lead to uncontrolled proliferation and the activation of metastatic genes, which can thereby result in neo-plastic transformation (Fig. 2).
### Table 1
Summary of aberrant actin isoform expression in various cancers.

| Actin Isoform | Cancer(s) in which it is aberrantly expressed | Upregulated or Downregulated | mRNA or Protein | Tumour cells or tumour tissue analysed | Clinical Outcome | Reference |
|---------------|-----------------------------------------------|-------------------------------|-----------------|----------------------------------------|------------------|----------|
| ACTA1         | Head and neck squamous cell carcinomas         | Downregulated                 | mRNA and protein | Cells and tissue                       | Correlated with greater aggressiveness and shorter survival | [24,25]  |
|               | Colorectal cancer                              |                               |                 |                                        |                  |          |
|               | Prostate                                      | Downregulated in the cancer,  | mRNA            | Tissue                                 |                  | [26]     |
|               |                                              | Upregulated in associated     |                 |                                        |                  | [29,31]  |
|               | cancer-associated fibroblasts                 |                               |                 |                                        |                  |          |
|               | Pancreatic adenocarcinoma                      | Downregulated                 | mRNA            | Cells and tissue                       |                  | [28]     |
|               | Oral squamous cell carcinoma                   |                               | mRNA            | Tissue                                 |                  | [32]     |
|               | Basal-like breast cancer                       | Upregulated                   | mRNA            | Tissue                                 | Associated with drug resistance | [33]     |
| ACTA2         | Lung adenocarcinoma                            | Upregulated                   | mRNA and protein| Cells and tissue                       | Shorter survival and early distant metastasis               | [44]     |
|               | HER2+ breast cancer                            | Upregulated                   | mRNA and protein| Cells and tissue                       | Shorter survival  | [43]     |
|               | Colorectal cancer                              | Upregulated in the cancer,    | mRNA and protein| Cells and tissue                       | Shorter disease-free survival                           | [45,49]  |
|               |                                              | Upregulated in associated     |                 |                                        |                  |          |
|               | cancer-associated fibroblasts                 |                               |                 |                                        |                  |          |
|               | Bladder cancer                                | Upregulated                   | mRNA            | Tissue                                 | Shorter survival  | [42]     |
|               | Non-small cell lung cancer                    |                               | Protein         | Cells                                   |                  | [46]     |
|               | Head and neck cancers                          | Upregulated in associated     | mRNA and protein| Cells and tissue                       | Shorter survival  | [47]     |
|               | cancer-associated fibroblasts                 |                               |                 |                                        |                  |          |
|               | Pancreatic cancer                              | Upregulated                   | mRNA and protein| Cells and tissue                       |                  | [48]     |
| ACTB          | Sarcoma                                       | Upregulated                   | Protein         | Cells                                   |                  | [36]     |
|               | Colon adenocarcinoma                           |                               | Protein         | Cells                                   |                  | [53]     |
|               | Hepatoma                                       | Upregulated                   | Protein         | Cells                                   | Greater metastatic potential                           | [54]     |
|               | Melanoma                                       | Upregulated                   | mRNA            | Cells                                   |                  | [58]     |
|               | Gastric cancer                                | Upregulated                   | mRNA            | Tissue                                 |                  | [62]     |
|               | oesophageal carcinoma                          | Upregulated                   | Protein         | Tissue                                 |                  | [39]     |
|               | Non-small cell lung cancer                    | Upregulated                   | mRNA            | Cells and tissue                       |                  | [61,63]  |
|               | Breast cancer                                 | Upregulated                   | mRNA            | Cells                                   |                  | [60]     |
|               | Lymphoma                                       | Upregulated                   | Protein         | Cells                                   |                  | [66]     |
|               | Cervical cancer                               | Downregulated                 | Protein         | Cells                                   |                  | [65]     |
| ACTC1         | Head and neck cancer                           | Upregulated                   | Protein         | Cells                                   | Greater distant metastasis                           | [76]     |
|               | Bladder cancer                                | Upregulated                   | mRNA            | Tissue                                 |                  | [79]     |
|               | Urothelial cancer                              | Upregulated                   | mRNA            | Tissue                                 |                  | [79]     |
|               | Prostate cancer                               | Upregulated                   | mRNA            | Tissue                                 | Predictor of the diseased/cancer state                | [78]     |
|               |                                              |                               |                 |                                        |                  |          |
|               | Non-small cell lung cancer                    | Upregulated                   | mRNA            | Cells                                   |                  | [80]     |
|               | Breast cancer                                 | Upregulated                   | mRNA            | Cells                                   | Multi-drug resistance                                | [81,82]  |
|               | Glioblastoma                                   | Upregulated                   | mRNA            | Cells                                   | Greater distant metastasis                           | [77,83]  |
|               | Skin cancer                                    | Upregulated                   | mRNA            | Tissue                                 |                  | [85]     |
| ACTG1         | Hepatocellular carcinoma                      | Upregulated                   | Protein         | Cells and tissue                       | Shorter survival and high expression is correlated to advanced tumour stage | [87]     |
|               | Non-clear cell renal cell carcinoma           | Upregulated                   | mRNA            | Tissue                                 |                  | [88]     |
|               | Colorectal cancer                              | Upregulated                   | Protein         | Cells                                   | Greater distant metastasis                           | [90]     |
|               | Lung cancer                                    | Upregulated                   | mRNA            | Cells                                   | Can serve as a biomarker for malignancy.              | [89]     |
|               | Cervical cancer                                | Upregulated                   | mRNA            | Tissue                                 |                  | [91]     |
|               | Acute lymphoblastic leukaemia                  | Downregulated                 | Protein         | Cells                                   | Resistance to microtubule-targeting agents            | [93]     |
|               | Neuroblastoma                                  | Downregulated                 | Protein         | Cells                                   | Greater distant metastasis                           | [86]     |
|               | Breast cancer                                  | Downregulated                 | Protein         | Cells                                   | Drug resistance to anti-mitotic agents                | [94]     |
|               |                                              |                               |                 |                                        |                  |          |
|               | Lung cancer                                    | Upregulated                   | Protein         | Tissue                                 |                  | [92]     |
|               | Colon cancer                                   | Upregulated                   | Protein         | Tissue                                 |                  | [92]     |
|               | Prostate cancer                                | Upregulated                   | Protein         | Cells                                   |                  | [92]     |
|               | Pancreatic cancer                              | Upregulated                   | Protein         | Cells                                   |                  | [92]     |
|               | Testicular cancer                              | Upregulated                   | Protein         | Cells                                   |                  | [92]     |
|               | Colorectal cancer                              | Upregulated                   | Protein         | Cells                                   |                  | [92]     |
|               | Oral squamous cell carcinoma                   | Upregulated                   | Protein         | Cells                                   |                  | [92]     |
| ACTG2         | Hepatocellular carcinoma                      | Upregulated                   | mRNA and protein| Cells and tissue                       | Correlated with EMT and aggressiveness             | [96,97]  |
**ACTB**

ACTB is a ubiquitously expressed cytoskeletal protein that plays a role in a wide variety of cellular functions such as cell growth, cell division, cell motility, immune response, gene expression, maintenance of cell stability and cytoskeletal formation [13,53–55]. These functions suggest that the deregulation of ACTB can play a role in cancer pathogenesis. Interestingly, increased ACTB levels have been reported in a number of highly metastatic tumour cell lines—sarcomas, colon adenocarcinomas, and hepatomas (Table 1) [53,54,56]. Its expression is found to be much higher than normal in invasive melanomas, gastric cancer, oesophageal carcinomas, non-small cell lung cancers, renal, aggressive breast cancers, and cervical cancers (Table 1) [57–65]. Notably, ACTB has also been found to be upregulated in drug-resistant lymphomas (Table 1) [66]. This isomorph is essential for the migratory capability of normal cells as knockdown results in decreased membrane protrusions at the leading edge of migrating cells, increased focal adhesion formation and increased expression of genes that regulate myosin activity [13].

The dynamic polymerization of actin is shown to contribute to tumour malignancy in some cancers [67–70]. In three adenocarcinoma cell lines with high ACTB expression, G-actin levels were found to have decreased while F-actin levels increased (Fig. 3). These cells demonstrate high metastatic potential and invasion, which is in line with the idea that the high level of actin polymerization is necessary for the formation of pseudopods and cancer cell invasion to the surrounding tissues (Fig. 3) [70,71]. ACTB may also play an essential role in maintaining cell growth potential. Work by Kwiatkowski et al [72], showed that loss of ACTB methylation by a protein called SET Domain Containing 3 (an actin histidine methyltransferase) leads to the depletion of F-actin and subsequent loss of cytoskeleton integrity (Fig. 3). This destabilization of the actin cytoskeleton through increased degradation of F-actin is a massive energy drain in the cell (causing up to 50% of total ATP consumption), and can in turn cause the cell to resort to anaerobic metabolism, which increases lactate production [72]. The accelerated degradation of the hypomethylated F-actin fibers is the reason for the increased demand of ATP and shift in cellular metabolism towards glycolysis [72]. The interplay between F-actin stability and ATP consumption is an important phenomenon to consider given the increased metabolic demands in cancer cells [73].

**ACTC1**

ACTC1 is a gene that encodes the major protein of the cardiac sarcomere thin filaments, which are responsible for cardiac muscle contraction [74]. Although it is expressed mainly in the heart and at lower levels in skeletal muscle, there is evidence for cardiac actin isoform expression during early mammalian neurodevelopment [75]. Interestingly, ACTC1 expression is shown to recur in many cancer types such as brain, head and neck, bladder, urothelial, prostate, lung, and breast cancers (Table 1) [76–82]. Furthermore, in patients with the malignant brain tumour glioblastoma (GBM), high ACTC1 mRNA expression may serve as a novel prognostic and invasion marker since it has been correlated with shorter survival and more frequent distant recurrence (Table 1) [77]. Wanibuchi et al. showed that ACTC1 mRNA knockdown in the U87 glioblastoma cells leads to impaired migration, which indicates its potential role in cell motility [83]. High ACTC1 expression has been associated with a lack of sensitivity to the mitotic inhibitor Paclitaxel in a lung cancer cell line and is also highly correlated with altered cell surface receptor linked signal transduction through sonic hedgehog.

---

![Fig. 3. A flow diagram of the different actin isoforms and how they contribute to tumorigenicity. ACTA1 = α_skeletal-actin 1, ACTA2 = α_smooth-actin 2, ACTB = β_skeletal-actin, ACTC1 = α_cardiac-actin 1, ACTG1 = γ_cytosol-actin 1 and ACTG2 = γ_smooth-actin 2.](image-url)
ACTG1

ACTG1 encodes for the cytoskeleton protein γ-actin which functions in non-muscle cells and is abundant in the auditory hair cells of the cochlea. This actin isoform is essential for the shape and function of stereocilia of hair cells, and plays a role in the internal cell motility [84,85]. Suppression of this isoform results in impaired migration of SH-EP neuroblastoma cells [86]. Interestingly, work by Dong et al [85]. showed that ACTG1 is expressed at significantly higher levels in skin cancer tissue (Table 1). It was also found that overexpressing ACTG1 in a squamous cell carcinoma cell line promotes growth and migration via inhibition of the ROCK pathway, leading to the reduction of myosin light chain phosphorylation (Fig. 3) [85]. In hepatocellular carcinomas, ACTG1 is overexpressed compared to adjacent normal tissues, and this promotes proliferation by upregulating cyclin-dependant kinases, inhibiting the mitochondrial apoptotic pathway, and promoting the Warburg effect by increasing cellular aerobic glycolysis, all which promote tumorigenesis (Fig. 3) [87]. A potential mechanism through which this works was found in non-clear cell renal cell carcinomas in which ACTG1 fuses with microphthalmia-associated transcription factor (MITF), and this dimer drives the transcription of downstream genes to promote anchorage-independent growth [88]. Corroborating with this finding, high ACTG1 expression is associated with greater metastatic potential and worse prognosis in hepatocellular carcinomas, colorectal cancer, lung cancer, cervical cancer (Table 1) [87,89–91]. The overexpression of ACTG1 has been associated with many malignant and invasive cancer types such as breast, lung, colon, prostate, pancreatic, testicular, colorectal, and oral squamous cancers (Table 1) [92].

Work by Dugina et al [92], shows that, the upregulation of γ-actins is induced by the downregulation of β-actins, while keeping the total cytoplasmic actin levels relatively the same, which supports the presence of endogenous compensatory mechanisms to maintain the homeoeostasis of actin isoforms. Interestingly, the downregulation of β-actin leads to a more motile cell phenotype while the downregulation of γ-actin induced a more contractile one. Overexpression of β-actin lead to a more “normal” phenotype and increasing γ-actin led to a more transformed one with a change in morphology to become more fan-like [92]. This suggests that the endogenous balance of actin isoforms can play a role in altering cell morphology and producing certain cancer phenotypes.

Interestingly, at the microtubule level, a decrease in ACTG1 levels in acute lymphoblastic leukaemia is associated with resistance to anti-microtubule drugs and protects microtubules from the action of both stabilizing and destabilizing agents (Table 1) [93]. This shows that the expression level of ACTG1 plays a role in regulating microtubule integrity. Microtubule disruption can activate RhoA and induce actomyosin contraction via myosin phosphorylation, which can in turn trigger tumorigenesis (Fig. 3) [93]. An experiment was performed in which ACTG1 was depleted in neuroblastoma and breast cancer cells, and this resulted in centrosome amplification, subsequent formation of multipolar spindles, as well as improper chromosome segregation, all which resulted in mitotic abnormalities [94]. Thus, γ-actin plays a role in maintaining centrosome integrity and regulating mitotic progression.

ACTG2

The final actin isoform that will be discussed is ACTG2, which is specifically expressed in smooth muscle cells of the intestinal and urogenital tracts, and functions in the contraction of smooth muscle in these organs [95]. In the context of hepatocellular carcinoma, ACTG2 is associated with epithelial to mesenchymal transition and the stem like properties of those cells. It also serves as a marker for aggressiveness of this cancer (Table 1) [96,97]. A reason for the increased oncogenic potential/aggressiveness and invasive ability of these cancer cells would be the activation of Notch1 signalling as well as ERK1/2 activation by ACTG2 (Fig. 3) [27,92,97]. Activation of the ERK-MAPK pathway leads to lamellipodial protrusions, which then leads to the subsequent activation of the WAVE2/Arp2/3 polymerization complex, resulting in actin reorganization [98–101]. Although this particular isoform has an important physiological role, literature on its dysregulation in the context of cancer is limited.

The role of actin in mitochondrial apoptotic signalling

Actin filaments can facilitate apoptosis signalling in cells. In fact, the polymerization of actin can regulate apoptosis via the intrinsic pathway. The disruption of actin filament dynamics by the drug Cytochalasin D, which binds the barbed end of F-actin preventing polymerization, can induce caspase 3-mediated apoptosis in T-lymphocytes [102]. Additionally, the release of pro-apoptotic Bmf from myosin V-actin complex upon Cytochalasin D treatment has also been found to induce mitochondria mediated apoptosis [103]. In mouse fibrosarcoma cells, Cytochalasin D induces mitochondrial cytochrome c release, which is a marker of mitochondrial permeability transition pore formation [104]. In yeast cells, actin point mutations that result in reduced actin dynamics or F-actin stabilizing drug Jasplakinolide increase the cell susceptibility to apoptosis due to mitochondrial membrane depolarization and accumulation of reactive oxygen species (ROS) [105]. γ G-actin from muscle is more effective than β or γ G-actin at reducing the conductance of mitochondrial voltage-dependant anion channels (VDACs) in the yeast Neurospora crassa [106]. This modulation of VDAC is lost in the presence of F-actin stabilization (Fig. 4) [106]. These observations indicate that alterations in actin dynamics and actin subunit expression may regulate the mitochondrial signal for intrinsic apoptosis.

Another possible mechanism whereby actin isoforms regulate cellular apoptosis is through modulating the opening of VDACs through direct or indirect protein-protein interactions [106,107]. Apart from regulating mitochondrial membrane potential, actin could also act down-stream of mitochondrial transition pore formation. To elaborate, actin has been shown to be cleaved by caspases to 32-kDa (Fractin) and 15-kDa (tActin) fragments [108]. The tActin fragment then undergoes N-myristoylation to target it to the mitochondria where it leads to mitochondrial transition pore formation, the caspase signalling cascade, and cellular morphological changes that resemble those observed in apoptotic cells [108,109]. Here, the change in isoform levels would alter formation of the tActin fragment in response to mitotic stress. Therefore, aberrant expression of actin isoforms may alter the propensity of cancer cells to undergo apoptosis (Fig. 4).

The effect of subunit composition on actin polymerization

The incorporation of new subunits into the already established F-actin network may disrupt its normal function (Fig. 4). It is believed that muscle and non-muscle actins do not incorporate into the same filaments in-vivo due to their higher amino acid divergence [110]. However, β- and γ-isoforms, which only differ by 4 amino acids in the N-terminal region distant from polymerization interfaces, can co-polymerize in mixtures of purified recombinant protein (Fig. 1) [111]. Under normal conditions, it has been found that ACT1 is able to incorporate into ACTA2 polymers in-vitro whereas ACTB and ACTG1 cannot [20]. The different localization of the ACTA1, ACTA2, ACTC1 and ACTG2 isoforms suggest that they may not co-polymerize in cells. For example, ACTC1 is localized at the sarcomere of cardiac (and muscle) cells, and co-expression of ACTA1 with ACTC1 and ACTA2 with ACTG2 did not affect localization of sarcomeric proteins [20,112–114].
Fig. 4. Flow diagram of the potential mechanisms by which altered F-actin composition can promote tumorigenicity.

To test the different stabilities of polymers formed by actin isoforms, rheological experiments were performed which revealed that the ACTA1 gel was most elastic, smooth muscle ACTB and ACTG2 gels were less elastic, and the cytoplasmic ACTB gel did not form an elastic gel at all [113,115]. Furthermore, the polymers formed by β- and γ-actin have a lower stability compared to sarcomeric α-actin, and in yeast, this lower stability of F-actin results in greater filament fragmentation [113]. The rate of filament turnover has a role in the mitotic stress response as well as in migration and invasion of cancer cells (Fig. 4) [116,117]. To support this further, it has been demonstrated that polypliodial giant cancer cells as well as breast cancer cells have more stress fibers of greater thickness and length [118,119]. These cells also show an upregulation of actin cytoskeletal elements, which results in stiffer gross-tumor rheological properties as well as increased migratory capability [119].

It has been found that α and β-actin as well as α and γ-actin copolymers show a linear relationship between the mixing ratio of actin subunits with respect to each other, as well as their resulting ATPase activity [120]. This hybrid F-actin behaves correspondingly to its isoform composition suggesting the independent function of each actin compared to one another [120]. This is interesting because β- and γ- actin polymers differ in their polymerization kinetics, inorganic phosphate release and treadmilling [111]. These biochemical differences between the two isoforms were exacerbated when Ca²⁺ was used with the actin rather than Mg²⁺ [19,111]. The preference for certain cations may allow cells to rapidly respond to signals by using a specific actin isoform [19,111]. A limitation that should be noted is that the co-polymerization of actin isoforms has only been studied in select cell types as it is generally assumed that copolymers do not commonly exist in vivo [120].

The rates of polymerization of F-actin appear to also depend on the isoform of the constituent subunits. α-, β- and γ-actins all have different rates of polymerization, resulting in different filament stabilities, elongation and turnover rates [111,121-123]. This in turn could affect cell survival during mitosis since cells undergoing mitosis experience increased plasma membrane tension and actively assemble a stiff actin cortex (Fig. 4) [124-126]. Taken together, the subunit composition of the F-actin network plays an important role in maintaining cell integrity during mitosis and abnormal constituents within the polymerized filament may result in a disease phenotype.

The role of actin isoforms in altering interactions with tropomyosin

Changes in tropomyosin (TM) isoform expression have been shown to accompany neoplastic cell transformation [127]. Furthermore, different TM isoforms show binding specificity to different F-actin isoforms [127]. When a human, rodent or chick fibroblasts are transfected with a non-cell-type specific isoform, the expression of its associated TMs is altered, suggesting that actin microfilament composition regulates tropomyosin expression [128-130]. It has been found that reverting this actin-initiated altered tropomyosin expression can also revert the cancer phenotype (i.e. cell spreading, microfilament organization and contact-inhibited cell growth) to a large extent in many cell types [127,131-135]. However, the synergistic restoration of the proper expression levels of multiple TM isoforms reverted the actin organization and ultimately the cancer phenotype of neuroblastomas as well as Ras-transformed NIH3T3 cells to a much greater extent than just one isofrom alone [127,135,136].

Mechanistically, aberrant actin isoform expression in cancer can result in abnormal actin-tropomyosin binding interactions within the cells, thereby causing greater actin polymerization at the leading edge and subsequent cellular contraction (Fig. 4) [137]. Dysregulated actin dynamics can be seen when an alteration to the filament occurs since this disrupts the electrostatic contacts between the F-actin and TM [138]. Altering TM-binding would affect the binding of ABPs such as cofilin as well as the loss of inhibition of actin filament branching and nucleation...
at the leading edge by the Arp2/3 complex. This will lead to altered polymerization/depolymerization kinetics and promote cell migration (Fig. 4) [11,139–141]. (Fig. 4) [141]. Furthermore, the resulting altered TM expression can work in conjunction with actin to affect rates of mammalian cell division and regulate cytokinesis through TM localization in the contractile ring of dividing cells to maintain cell stiffness (Fig. 4) [142,143]. Lastly, the abnormal expression of TM can impact organelle trafficking and the contacts of different myosin motors with actin, all which all which affects downstream cellular pathways (Fig. 4) [144–146].

By the same token, different tropomodulin (Tmod) isoforms are also found in regions where their preferred actin isoform binding partner is located. For example, Tmod1 is abundant in post-mitotic, terminally differentiated cells [147]. Tmod3 is mainly found in dynamic cellular contexts such as those of the dendritic actin network in the leading lamellipodia of migrating endothelial cells as well as in proliferating erythroblasts [147]. Tmods1 and 3 cap the pointed ends of ACTA1, ACTB and ACTG1 [147]. However, in the absence of tropomyosin, only Tmod3 could sequester ACTB and ACTG1, but not ACTA2 [147]. Tmod1 can induce conformation changes in a/βTM and ACTA1, thereby potentially activating downstream molecular pathways (Fig. 3) [147].

**Altered ABP interactions due to changes in actin polymerization**

Differences in actin isoforms can be found with the acidic residues at the NH2-terminus between actin isoforms, which acts like a fishing rod to recruit ABPs (Fig. 1) [148–150]. Thus, variations in this region can modulate the binding affinities of different ABPs such as cofilin, utrophin, formin and myosin, resulting in altered actin polymerization kinetics, cell migration, adhesion, cytokinesis, and cytoskeletal maintenance (Fig. 4) [151–156]. For example, the greater affinity of cofilin to β and γ-actins compared to α-actin implies that smaller amounts of cofilin will cause those actin filaments to twist and sever [157]. Furthermore, the upregulation of TMs 1.1, 1.2 and 3.1, which is a consequence of aberrant actin isoform expression, can cause increased binding of gelsoin, which will also increase its rates of actin assembly and disassembly [158]. Taken together, this suggests that changes in the rates of actin assembly-disassembly, polymerization, elongation and severing which can have downstream effects in the intracellular trafficking, cell migration, and proliferation.

**Clinical translation**

An understanding of the diversity of actin subunit expression and function in multiple cancers may help to stratify patients into higher risk groups which may benefit from different treatment strategies. Furthermore, understanding how expression of subunits such as ACTA1, ACTA2, ACTB, ACTC1, and ACTG1 can promote chemoresistance against anti-microtubule agents in certain tumours could help to design new therapies to overcome such resistance. Drugs that disrupt actin polymerization or induce filament severing have been previously described; however, a major challenge in using these drugs in patients is that they would disrupt actin function in all cells in the body [159]. Recently, a more targeted approach aiming to disrupt specific tropomyosin interactions with actin has been presented. Small molecule inhibitors of TM 3.1 such as TR100 and ATM-3507 are used to destabilize TM 3.1-containing filaments with great effectiveness in vitro and in vivo [160–162]. Another approach to target the actin cytoskeleton would be through the use of migrastatic agents that target actin polymerization. These include actin destabilizing compounds (i.e. cytochalasins, geodiamidoses, and latrunclins), as well as stabilizing compounds that initiate dysregulated polymerization, monomer depletion, or formation of actin aggregates (i.e. jasplakinolide, chondramide, and cucurbicitin). The goal of this approach is to effectively inhibit cell invasion and metastasis [163]. Further understanding of the specific interactions of actin subunits that result in sustaining migration and cell survival may provide new avenues for rational design of drugs targeting aberrant actin signalling in cancer cells with less toxicity to normal cells.

**Conclusion**

In conclusion, actin has diverse biological function beyond just maintaining the structural integrity of cells or regulating cell motility. The actin composition of cells and subsequent altered F-actin properties can contribute to neoplastic transformation by driving tumour growth and promoting metastasis. Studying this fundamental change that takes place within cancer cells can further our understanding of oncogenesis. Furthermore, aberrant actin isoform expression could be used as a biomarker for the early onset of cancer, serve as a potential therapeutic target, and even act as an indicator for the efficacy of currently used chemotherapeutic agents.

**Author contributions**

**Rahul Suresh**: Methodology, Writing - original draft preparation, Visualization

**Roberto Jose Diaz**: Conceptualization, Writing - reviewing and editing, Supervision

**Declaration of Competing Interest**

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

**Funding**

Foundation of the Department of Neurosurgery and the Montreal Neurological Institute for funding the costs of publication.

**References**

[1] R. Dominguez, K.C. Holmes, Actin structure and function, Ann. Rev. Biophys. 40 (2011) 169–186.
[2] B.J. Perrin, J.M. Ervasti, The actin gene family: function follows isoform, Cytoskeleton (Hoboken) 67 (10) (2010) 630–634.
[3] R.W. Ruddon, What makes a cancer cell a cancer cell? Cancer Medicine, 6th edition ed., BC Decker, Hamilton (ON), 2003.
[4] V.E. Franklin-Tong, C.W. Gourlay, A role for actin in regulating apoptosis/programmed cell death: evidence spanning yeast, plants and animals, Biochem. J. 413 (3) (2008) 389–404.
[5] J.R. Stehn, et al., A novel class of anticancer sigma compounds targets the actin cytoskeleton in tumor cells, Cancer Res. 73 (16) (2013) 5169–5182.
[6] C.G. dos Remedios, et al., Actin binding proteins: regulation of cytoskeletal microfilaments, Physiol. Rev. 83 (2) (2003) 433–473.
[7] N. Courtemanche, Mechanisms of formin-mediated actin assembly and dynamics, Biophys. Rev. 10 (6) (2018) 1553–1569.
[8] M. Edwards, et al., Capping protein regulators fine-tune actin assembly dynamics, Nat. Rev. Mol. Cell Biol. 15 (10) (2014) 677–689.
[9] D.M. Helfman, et al., Tropomyosins as a regulator of cancer cell transformation, in: Tropomyosins, Springer, 2008, pp. 124–131.
[10] P.W. Gunning, et al., Tropomyosin - master regulator of actin filament function in the cytoskeleton, J. Cell. Sci. 128 (16) (2015) 2965–2974.
[11] W. Lehman, et al., Tropomyosin and actin isoforms modulate the localization of tropomyosin strands on actin filaments, J. Mol. Biol. 302 (3) (2000) 593–606.
[12] L.A. Beloyantsyeva, et al., Gamma-actin is required for cytoskeletal maintenance but not development, Proc. Natl. Acad. Sci. USA, 106 (24) (2009) 9703–9708.
[13] T.M. Bunnell, et al., beta-Actin specifically controls cell growth, migration, and the G-actin pool, Mol. Biol. Cell 22 (21) (2011) 4047–4058.
[14] T.M. Bunnell, J.M. Ervasti, Delayed embryonic development and impaired cell growth and survival in Actg1 null mice, Cytoskeleton (Hoboken) 67 (9) (2010) 564–572.
[15] K. Crawford, et al., Mice lacking skeletal muscle actin show reduced muscle strength and growth deficits and die during the neonatal period, Mol. Cell. Biol. 22 (16) (2002) 5887–5896.
[16] A. Kumar, et al., Rescue of cardiac alpha-actin-deficient mice by enteric smooth muscle gamma-actin, Proc. Natl. Acad. Sci. USA 94 (9) (1997) 4406–4411.
[17] L.A. Schildmeyer, et al., Impaired vascular contractility and blood pressure homeostasis in the smooth muscle alpha-actin null mouse, FASEB J. 14 (14) (2000) 2213–2220.
can result in diffuse and diverse vascular diseases: evidence for a hyperplastic vasculopathy, Genet. Med. 12 (4) (2010) 196–203.

[53] D. Nowak, et al., Beta-actin in human colon adenocarcinoma cell lines with different metastatic potential, Protoplasma. Biochim. Pol. 52 (2) (2005) 461–468.

[54] A. Popow, D. Nowak, Malicka-Blazkiewicz, Actin cytoskeleton and beta-actin expression in correlation with higher invasiveness of selected hepatoma Morris 5123 cells, J. Physiol. Pharmacol. 57 (Suppl 7) (2006) 111–123.

[55] W. Hui, M. Lai, Actin, a reliable marker of internal control? Clin. Chim. Acta. 385 (1–2) (2007) 1–5.

[56] P.U. Le, et al., Increased beta-actin expression in an invasive melanoma sarcoma virus-transformed MDCK cell variant concentrates to the tips of multiple pseudopodia, Cancer Res. 58 (9) (1998) 1534–1537.

[57] C. Blanquicett, et al., Housekeeping gene variability in normal and carcinomatous colorectal and liver tissues: applications in pharmacogenomic expression studies, Anal. Biochem. 303 (2) (2002) 209–214.

[58] D. Alba, et al., Ribbin, R. R., RNAse D1 DNA prevails over glyceroldehyde-3-phosphate dehydrogenase and beta-actin genes as internal standard for quantitative comparison of mRNA levels in invasive and noninvasive human melanoma cell subpopulations, Anal. Biochem. 295 (1) (2001) 17–21.

[59] Z. Liu, et al., Proteomic identification of differentially-expressed proteins in esophageal cancer in three ethnic groups in Xining, Mol. Biol. Rep. 38 (5) (2011) 3261–3269.

[60] D.L. Morse, et al., Determining suitable internal standards for mRNA quantification of increasing cancer progression in human breast cells by real-time reverse transcriptase polymerase chain reaction, Anal. Biochem. 342 (1) (2005) 69–77.

[61] P.A. Nguwu, et al., Identification of importin 8 (IPO8) as the most accurate reference gene for the clinicopathological analysis of lung specimens, BMC Mol. Biol. 9 (2008) 103.

[62] C. Rubie, et al., Housekeeping gene variability in normal and cancerous colorectal, pancreatic, esophageal, gastric and hepatic tissues, Mol. Cell Probes 19 (2) (2005) 101–110.

[63] S. Saviozzi, et al., Selection of suitable reference genes for accurate normalization of gene expression profile studies in non-small cell lung cancer, BMC Cancer 6 (2006) 200.

[64] R.E. Ferguson, et al., Housekeeping proteins: a preliminary study illustrating some limitations as useful references in protein expression studies, Proteomics 5 (2) (2005) 566–571.

[65] G.S. Shagieva, et al., Actin isoforms and reorganization of adhesion junctions in epithelial-to-mesenchymal transition of cervical carcinoma cells, Biochemistry (Mosc.) 77 (11) (2012) 1266–1276.

[66] M. Weinkauf, et al., 2-D PAGE-based comparison of proteasome inhibitor bortezomib in sensitive and resistant mantle cell lymphoma, Electrophoresis 30 (6) (2009) 794–806.

[67] A. Ben-Ze'ev, Cytoskeletal and adhesion proteins as tumor suppressors, Curr. Opin. Cell Biol. 9 (1) (1997) 99–108.

[68] F. Decoutre, et al., Concomitant alterations of microfilaments and microtubules in human epithelial cells (HBL-100) in relation to their malignant conversion, Tumour Biol. 12 (2) (1991) 111–119.

[69] P. Frontelo, et al., Transforming growth factor beta 1 induces squamous carcinoma cell variants with increased metastatic abilities and a disorganized cytoskeleton, Exp. Cell Res. 244 (2) (1998) 341–346.

[70] C.R. Liu, et al., Differential thymosin beta 10 expression levels and actin filament organization in tumor cell lines with different metastatic potential, Chin. Med. J. (Engl.) 117 (2) (2004) 213–218.

[71] C. Guo, et al., ACTG1 in breast cancer Clin Chim Acta 417 (2013) 39–44.

[72] S. Kwatkiowski, et al., S100D protein is the actin-specific histidine N-methyltrans- ferase, Elife 7 (2018).

[73] L. Yu, et al., The Glycolytic Switch in Tumors: how Many Players Are Involved? J. Cancer 6 (2) (2015) 1358–1354.

[74] L. Prouell, et al., Influence of cytoskeleton organization on recombinant protein expression by CHO cells, Biotechnol. Bioeng. 117 (4) (2020) 1117–1126.

[75] F. Poggiolidoso, et al., A chronological expression profile of gene activity during embryonic mouse brain development, Mamm. Genome 24 (11–12) (2013) 459–472.

[76] R.G. da Rocha, et al., Leptin impairs the therapeutic effect of ionizing radiation in oral squamous cell carcinoma cells, J. Oral Pathol. Med. 48 (1) (2019) 17–23.

[77] S. Ohtaki, et al., ACTG1 as an invasion and prognosis marker in glioma, J. Neuro- oncol. 126 (2) (2017) 467–475.

[78] H.C. Huang, et al., Discovering disease-specific biomarker genes for cancer diag- nosis and prognosis, Technol. Cancer Res. Treat. 9 (3) (2010) 219–230.

[79] A. Zaravinos, et al., Identification of common differentially expressed genes in urinary bladder cancer, PLoS ONE 6 (4) (2011) e18355.

[80] C.L. Che, et al., DNA microarray reveals different pathways responding to paclitaxel and docetaxel in non-small cell lung cancer cell line, Int. J. Clin. Exp. Pathol. 6 (8) (2013) 1538–1548.

[81] Y. Li, G. Rong, H. Kang, Taxotere-induced elevated expression of IL8 in carcinoma-associated fibroblasts of breast invasive ductal cancer, Oncol. Lett. 13 (3) (2017) 1856–1860.

[82] M. Someya, et al., Identification of genes and pathways associated with MDR in MCF-7/MDR breast cancer cells by RNA-seq analysis, Mol. Med. Rep. 17 (5) (2018) 6211–6226.

[83] M. Waniebuchi, et al., Actin, alpha, cardiac muscle 1 (ACTC1) knockdown inhibits the migration of glioblastoma cells in vitro, J. Neurol. Sci. 392 (2018) 117–121.

[84] C.G. Lee, J. Jang, H.S. Jin, A novel missense mutation in the ACTG1 gene in a family with congenital autosomal dominant deafness: a case report, Mol. Med. Rep. 17 (6) (2018) 7611–7617.
log beta-like actin and rabbit skeletal muscle alpha-actin, Arch. Biochem. Biophys. 368 (1) (1999) 105–111.

123. S. Khaitlina, H. Hinsken, Difference in polymerization and steady-state dynamics of free and gelosin-capped filaments formed by alpha- and beta-isoactins, Arch. Biochem. Biophys. 477 (2) (2008) 279–284.

124. P. Kundra, et al., Moesin controls cortical rigidity, cell rounding, and spindie morphogenesis during mitosis, Curr. Biol. 18 (2) (2008) 91–101.

125. H.L. Kettes, et al., Death receptor expression in colon cancer: a role in cell survival and apoptosis, Cancer Res. 62 (2002) 371–383.

126. D. Raucher, M.P. Sheetz, Membrane expansion increases endocytosis rate during mitosis, J. Cell Biol. 144 (3) (1999) 497–506.

127. F. Groning, G. O’Neill, E. Hardeman, Tropomyosin-beta regulation of the actin cytoskeleton in time and space, Physiol. Rev. 88 (1) (2008) 1–35.

128. J. Leavitt, et al., Expression of transfected mutant beta-actin genes: transitions towards to the stable tumorogenic state, Mol. Cell. Biol. 7 (7) (1987) 2467–2476.

129. J. Leavitt, et al., Tropomyosin and actin switching in tumorgenic human fibroblasts, Mol. Cell. Biol. 6 (7) (1986) 2721–2726.

130. F. Matsumura, Y. Yamashiro-Matsumura, Purification and characterization of multiple isoforms of tropomyosin from rat cultured cells, J. Biol. Chem. 265 (20) (1985) 13851–13859.

131. M. Gionma, J.A. Kazazz, D.M. Helfand, Forced expression of tropomyosin 2 or 3 in v-Ki-ras-transformed fibroblasts results in distinct phenotypic effects, Proc. Natl. Acad. Sci. USA, 93 (1996) 9618–9623.

132. K. Mahadev, et al., Suppression of the transformed phenotype of breast cancer by tropomyosin-1, Exp. Cell Res. 279 (1) (2002) 40–51.

133. G.L. Prasad, R.A. Fuldner, H.L. Cooper, Expression of transfused tropomyosin 1 cDNA suppresses neoplastic growth of cells transformed by the ras oncogene, Proc. Natl. Acad. Sci. USA, 93 (1996) 7039–7045.

134. G.L. Prasad, et al., Suppression of src-induced transformed phenotype by expression of tropomyosin-1, Oncogene 18 (11) (1999) 2027–2031.

135. V. Shah, et al., Cytoskeletal organization in tropomyosin-mediated reversion of transformation: evidence for Rho kinase pathway, Oncogene 20 (17) (2001) 2112–2121.

136. M.L. Yager, et al., Functional analysis of the actin-binding protein, tropomyosin 1, in neuroblastoma, Br. J. Cancer 89 (5) (2003) 860–863.

137. C.L. Wang, L.M. Coluccio, New insights into the regulation of the actin cytoskeleton by tropomyosin, Int. Rev. Cell Mol. Biol. 281 (2010) 91–128.

138. M.C. Viswanathan, et al., A role for actin flexibility in thin filament-mediated contractile regulation and myosin, Nat. Commun. 11 (1) (2020) 2417.

139. S.E. Hitchcock-DeGregori, P. Sampath, T.D. Pollard, Tropomyosin inhibits the rate of actin polymerization by stabilizing actin filaments, Biochemistry 27 (26) (1988) 9182–9185.

140. H. Vindin, P. Groning, Cytoskeletal tropomyosin: choreograph of filament survival and motility in the cell, J. Muscle Res. Cell Motil. 34 (3-4) (2013) 261–274.

141. L. Blanchin, T.D. Pollard, S.E. Hitchcock-DeGregori, Inhibition of the Arp2/3 complex-nucleated actin polymerization and branch formation by tropomyosin, Curr. Biol. 11 (16) (2001) 1300–1304.

142. R.D. Eppinga, et al., Tropomyosin and caldesmon regulate cytokinesis speed and membrane stability during cell division, Arch. Biochem. Biophys. 456 (2) (2006) 161–174.

143. J.A. Hughes, et al., High molecular-weight tropomyosin localizes to the contractile rings of dividing CNS cells but are absent from malignant pediatric and adult CNS tumors, Glia 42 (1) (2003) 25–35.

144. A.J. Kee, et al., An actin filament population defined by the tropomyosin Tpm3.1 intermediate filament gene regulates glucose uptake in human colon cancer cells, J. Biol. Chem. 277 (24) (2002) 21191–21202.

145. B.B. McIntosh, E.L. Holzbaur, E.M. Ostap, Control of the initiation and termination of kinesin-1-driven transport by myosin-Ic and nonmuscle tropomyosin, Curr. Biol. 25 (4) (2015) 523–529.

146. N. Tang, E.M. Ostap, Lamin B1–domain dependent localization of myo1b (myr-1), Curr. Biol. 11 (14) (2001) 1131–1135.

147. S. Yamashiro, et al., Differential actin-regulatory activities of Tropomodulin1 and Tropomodulin3 with diverse tropomyosin and actin isoforms, J. Biol. Chem. 289 (17) (2014) 11616–11629.

148. J. Vandekerckhove, K. Weber, At least six different actins are expressed in a higher mammal: an analysis based on the amino acid sequence of the amino-terminal tryptic peptide, J. Mol. Biol. 126 (4) (1978) 785–802.

149. J. Vandekerckhove, K. Weber, Actin typing on total cellular extracts: a highly sensitive protein-chemical procedure able to distinguish different acts, Eur. J. Biochem. 113 (3) (1981) 595–603.

150. M. Van Troye, J. Vandekerckhove, C. Ampe, Structural modules in actin-binding proteins: toward a general classification, Biochim. Biophys. Acta 1448 (3) (1999) 323–348.

151. N. Oneyazawa, et al., An actin-interacting heptapeptide in the cofilin sequence, Eur. J. Biochem. 183 (1) (1990) 235–239.

152. S. Khaitlina, et al., Tropomyosin-beta regulation of the actin cytoskeleton in time and space, J. Biol. Chem. 272 (11) (1997) 6565–6572.
[157] E.M. De La Cruz, Cofilin binding to muscle and non-muscle actin filaments: isoform-dependent cooperative interactions, J. Mol Biol. 346 (2) (2005) 557–564.

[158] N. Kis-Bicskei, et al., Tropomyosins regulate the severing activity of gelsolin in isoform-dependent and independent manners, Biophys. J. 114 (4) (2018) 777–787.

[159] M.A. Jordan, L. Wilson, Microtubules and actin filaments: dynamic targets for cancer chemotherapy, Curr. Opin Cell Biol. 10 (1) (1998) 123–130.

[160] T.T. Bonello, et al., A small molecule inhibitor of tropomyosin dissociates actin binding from tropomyosin-directed regulation of actin dynamics, Sci. Rep. 6 (2016) 19816.

[161] M.A. Currier, et al., Identification of cancer-targeted tropomyosin inhibitors and their synergy with microtubule drugs, Mol. Cancer Ther. 16 (8) (2017) 1555–1565.

[162] Y. Wang, et al., Drug targeting the actin cytoskeleton potentiates the cytotoxicity of low dose vincristine by abrogating actin-mediated repair of spindle defects, Mol. Cancer Res. 18 (7) (2020) 1074–1087.

[163] A. Gandalovicova, et al., Migrastatics-anti-metastatic and anti-invasion drugs: promises and challenges, Trends Cancer 3 (6) (2017) 391–406.